GlassScriptPhysician profile
Timothy M Lopez
NPI 1174521983
$2,542.12
in general payments reported to CMS, 2019-2025
36 companies · $570 in 2025
The $570 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.91 · 2021: $23.89 · 2022: $334 · 2023: $816 · 2024: $707 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041 · Education: $51.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.80 |
| Education | $51.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $309.96 | 2019-2025 | Trodelvy |
| Pfizer INC. | $214.12 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $204.55 | 2022-2025 | |
| Abbvie INC. | $197.25 | 2023-2025 | |
| Exelixis INC. | $187.60 | 2023-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $175.93 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $121.74 | 2022 | |
| Janssen Biotech, INC. | $121.53 | 2022-2025 | Erleada, Akeega, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $79.60 | 2019-2025 | Opdivo, Krazati |
| Merck Sharp & Dohme LLC | $77.46 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $76.65 | 2023-2025 | Lynparza, Imfinzi |
| Mirati Therapeutics, INC. | $75.56 | 2023-2024 | Krazati |
| Array Biopharma INC | $75.44 | 2023-2024 | Braftovi, Mektovi, Lorbrena |
| Emd Serono, INC. | $69.44 | 2023-2024 | Bavencio |
| Kite Pharma, INC. | $59.75 | 2023-2025 | Yescarta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $52.24 | 2023-2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $47.23 | 2019-2022 | |
| Seagen INC. | $46.16 | 2022-2023 | Adcetris |
| Stemline Therapeutics INC. | $42.31 | 2024-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $27.22 | 2023 | Imbruvica |
| Adaptive Biotechnologies Corporation | $23.83 | 2023 | Clonoseq |
| Jazz Pharmaceuticals INC. | $21.73 | 2023 | |
| Agios Pharmaceuticals, INC. | $21.73 | 2024 | |
| Celgene Corporation | $20.69 | 2023 | Reblozyl |
| Genzyme Corporation | $20.61 | 2023 | |
| Beigene USA, INC. | $19.39 | 2023 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $18.33 | 2024 | Rolvedon |
| Amgen INC. | $17.79 | 2023 | Kyprolis, Blincyto |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Pharmaessentia USA Corporation | $16.34 | 2023 | Besremi |
| Astellas Pharma US INC | $15.10 | 2025 | Xtandi |
| Tempus Ai, INC | $15.09 | 2025 | Xt Cdx |
| Genentech USA, INC. | $14.70 | 2019 | |
| Lilly USA, LLC | $13.50 | 2023 | Verzenio |
| Taiho Oncology, INC. | $12.56 | 2022 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.